摘要
目的观察长春瑞滨(NVB)加奥沙利铂(LOHP)治疗老年晚期非小细胞肺癌(NSCLC)的临床疗效及毒副反应。方法对54例经病理组织学或细胞学证实的晚期非小细胞肺癌患者,随机分为治疗组28例及对照组26例,分别给予NVB+LOHP及NVB+CDDP治疗,每28天为一个周期,均治疗2周期以上。结果治疗组总有效率为39.3%,对照组总有效率为38.5%(P>0.05)。毒副反应以白细胞降低、胃肠道反应和周围神经炎为主,而Ⅲ～Ⅳ度消化道反应、肾脏损害主要发生在对照组,周围神经炎主要发生在治疗组(P<0.05),毒副反应均可耐受。结论长春瑞滨(NVB)加奥沙利铂与长春瑞滨(NVB)加顺铂治疗老年晚期非小细胞肺癌疗效相仿,均有较好的近期疗效,但长春瑞滨(NVB)加奥沙利铂组的毒副反应较轻,临床应用较安全,更适合于老年患者。
Objective To evaluate the efficacy and toxicity of vinorelbine and oxaliplatin in the treatment of elderly and advanced non-small cell lung cancer （NSCLC）. Methods A total of 54 patients with elderly advanced NSCLC diagnosed by pathology were randomly divided into two groups. Vinorelbine and oxaliplatin were administrated to the patients in the study group （ n = 28 ）, and vinorelbine and cisplatin in the control group（ n = 26）, with 28 days as a cycle. All patients received at least two cycles. Results The overall response rate was 39. 3 % in the study group and 38.5 % in the control group （ P 〉 0. 05 ）. The main toxicities were well tolerated and consisted of leucopenia, nausea/vomiting and peripheral neuritis. Grades m. IV nan sea/vomiting,renal toxicity occurred more frequently in the control group, and peripheral neuritis occurred more frequently in the study group （ P 〈 0. 05 ）. Conclusion Both of the two regimens of vinorelbine plus oxaliplatin and vinorelbine plus cisp]atin are feasible, well-tulerated and effective in the treatment of advanced NSCLC, and the former may be safer than the latter for the older patients.
出处
《临床肺科杂志》
2009年第10期1309-1310,共2页
Journal of Clinical Pulmonary Medicine
关键词
非小细胞肺癌
老年
长春瑞滨
奥沙利铂
顺铂
non-small lung cancer
elderly
vinorelbine
oxaliplatin
cisplatin
